Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against Influenza A(H1N1)pdm09 Virus Infection in BALB/c mice

Clinical and Vaccine Immunology

Volumn 21, Issue 4, 2014, Pages 570-579

  Zhang, Anna J X ^a   Li, Can ^a   To, Kelvin K W ^a   Zhu, Hou Shun ^a   Lee, Andrew C Y ^a   Li, Chuan Gen ^a   Chan, Jasper F W ^a   Hung, Ivan F N ^a   Yuen, Kwok Yung ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; IMIQUIMOD; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; NEUTRALIZING ANTIBODY; RIBONUCLEASE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTOR; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; INFLUENZA A (H1N1); INFLUENZA A (H5N1); MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD; AGONISTS; ANIMAL; BLOOD; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL;

AMINOQUINOLINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 7;

EID: 84897937018     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00816-13     Document Type: Article

References (51)

1. Cheng VC, To KK, Tse H, Hung IF, Yuen KY. 2012. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin. Microbiol. Rev. 25:223-263. http://dx.doi.org/10.1128/CMR.05012-11.
2. Hung IF, Leung AY, Chu DW, Leung D, Cheung T, Chan CK, Lam CL, Liu SH, Chu CM, Ho PL, Chan S, Lam TH, Liang R, Yuen KY. 2010. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin. Infect. Dis. 51:1007-1016. http://dx.doi.org/10.1086/656587.
3. Centers for Disease Control and Prevention. 2013. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014. MMWR Recomm. Rep. 62(RR-07):1-43. (Erratum, 62:906.)
4. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11)-70295-X.
5. Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY. 2012. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 30:6427-6435. http://dx.doi.org/10.1016/j.vaccine.2012.08.014.
6. Hung IF, Levin Y, To KK. 2012. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 30:2707-2708. http://dx.doi.org/10.1016/j.vaccine.2011.12.069.
7. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, Compans R, Pulendran B. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547. http://dx.doi.org/10.1038/nature09737.
8. Pashine A, Valiante NM, Ulmer JB. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11:S63-S68. http://dx.doi.org/10.1038/nm1210. (Pubitemid 40562305)
9. Demento SL, Eisenbarth SC, Foellmer HG, Platt C, Caplan MJ, Mark Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell RA, Fahmy TM. 2009. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27:3013-3021. http://dx.doi.org/10.1016/j.vaccine.2009.03.034.
10. Melchjorsen J. 2013. Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines. Viruses 5:470-527. http://dx.doi.org/10.3390/v5020470.
11. Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995. http://dx.doi.org/10.1038/ni1112. (Pubitemid 41057715)
12. Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, Lerumo L, Hughes J, Hussey G, Hawkridge A, Kaplan G, Hanekom WA, Hawn TR, South African Tuberculosis Vaccine Initiative T. 2011. Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. PLoS Pathog. 7:e1002174. http://dx.doi.org/10.1371/journal.ppat. 1002174.
13. Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ. 2007. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178: 2182-2191. (Pubitemid 46233416)
14. Lim KH, Staudt LM. 2013. Toll-like receptor signaling. Cold Spring Harb. Perspect. Biol. 5:a011247. http://dx.doi.org/10.1101/cshperspect.a011247.
15. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 101:5598-5603. http://dx.doi.org/10. 1073/pnas.0400937101. (Pubitemid 38481202)
16. Jeisy-Scott V, Kim JH, Davis WG, Cao W, Katz JM, Sambhara S. 2012. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice. J. Virol. 86:10988-10998. http://dx.doi.org/10.1128/JVI. 01064-12.
17. Welte T, Reagan K, Fang H, Machain-Williams C, Zheng X, Mendell N, Chang GJ, Wu P, Blair CD, Wang T. 2009. Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. J. Gen. Virol. 90:2660-2668. http://dx.doi.org/10.1099/vir.0.011783-0.
18. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. 2010. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115:1949-1957. http://dx.doi.org/10.1182/blood-2009-08-238543.
19. Kaminski MM, Ohnemus A, Cornitescu M, Staeheli P. 2012. Plasmacytoid dendritic cells and Toll-like receptor 7-dependent signalling promote efficient protection of mice against highly virulent influenza A virus. J. Gen. Virol. 93:555-559. http://dx.doi.org/10.1099/vir.0.039065-0.
20. Mouriès J, Moron G, Schlecht G, Escriou N, Dadaglio G, Leclerc C. 2008. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112:3713-3722. http://dx.doi.org/10.1182/blood- 2008-03-146290.
21. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, Kawai T, Akira S. 2007. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179:4711-4720.
22. Boeglin E, Smulski CR, Brun S, Milosevic S, Schneider P, Fournel S. 2011. Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells. PLoS One 6:e25542. http://dx.doi.org/10.1371/journal.pone.0025542.
23. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF. 2012. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur. J. Immunol. 42:863-869. http://dx.doi.org/10.1002/eji.201041225.
24. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A. 2008. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 4:e1000138. http://dx.doi.org/10.1371/journal.ppat. 1000138.
25. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA. 2005. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 102:15190-15194. http://dx.doi.org/10.1073/pnas.0507484102. (Pubitemid 41513357)
26. Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, Kitchener HC, Einstein MH. 2012. Therapy of human papillomavirus-related disease. Vaccine 30(Suppl 5):F71-F82. http://dx.doi.org/10.1016/j.vaccine.2012. 05.091.
27. Othoro C, Johnston D, Lee R, Soverow J, Bystryn JC, Nardin E. 2009. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect. Immun. 77:739-748. http://dx.doi.org/10.1128/IAI.00974-08.
28. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP. 2002. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218:74-86. http://dx.doi.org/10.1016/S0008- 8749(02)00517-8. (Pubitemid 36027092)
29. Russo C, Cornella-Taracido I, Galli-Stampino L, Jain R, Harrington E, Isome Y, Tavarini S, Sammicheli C, Nuti S, Mbow ML, Valiante NM, Tallarico J, De Gregorio E, Soldaini E. 2011. Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells. Blood 117:5683-5691. http://dx.doi.org/10.1182/blood-2010-12-328138.
30. To KK, Chan JF, Chen H, Li L, Yuen KY. 2013. The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infect. Dis. 13:809-821. http://dx.doi.org/10.1016/S1473-3099(13)70167-1.
31. To KK, Ng KH, Que TL, Chan JM, Tsang KY, Tsang AK, Chen H, Yuen K. 2012. Avian influenza A H5N1 virus: a continuous threat to humans. Emerg. Microbes Infect. 1:e25. http://dx.doi.org/10.1038/emi.2012.24.
32. Carrat F, Flahault A. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852-6862. http://dx.doi.org/10.1016/j.vaccine.2007.07.027. (Pubitemid 47398929)
33. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945-1952. http://dx.doi.org/10.1056/NEJMoa0906453.
34. Zhang AJ, To KK, Tse H, Chan KH, Guo KY, Li C, Hung IF, Chan JF, Chen H, Tam S, Yuen KY. 2011. High incidence of severe influenza among individuals over 50 years of age. Clin. Vaccine Immunol. 18:1918-1924. http://dx.doi.org/10.1128/ CVI.05357-11.
35. Chan KH, Zhang AJ, To KK, Chan CC, Poon VK, Guo K, Ng F, Zhang QW, Leung VH, Cheung AN, Lau CC, Woo PC, Tse H, Wu W, Chen H, Zheng BJ, Yuen KY. 2010. Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice. PLoS One 5:e13757. http://dx.doi.org/10.1371/journal.pone.0013757.
36. Zhang AJ, To KK, Li C, Lau CC, Poon VK, Chan CC, Zheng BJ, Hung IF, Lam KS, Xu A, Yuen KY. 2013. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J. Infect. Dis. 207: 1270-1280. http://dx.doi.org/10.1093/infdis/jit031.
37. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, Chen HL, Wong SS, Lau SK, Woo PC, Chan KH, Jin DY, Yuen KY. 2008. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. U. S. A. 105:8091-8096. http://dx.doi.org/10.1073/pnas.0711942105. (Pubitemid 351904713)
38. To KK, Zhang AJ, Hung IF, Xu T, Ip WC, Wong RT, Ng JC, Chan JF, Chan KH, Yuen KY. 2012. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin. Vaccine Immunol. 19:1012-1018. http://dx.doi.org/10.1128/CVI.00081-12.
39. Chan KH, To KK, Hung IF, Zhang AJ, Chan JF, Cheng VC, Tse H, Che XY, Chen H, Yuen KY. 2011. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin. Vaccine Immunol. 18:867-873. http://dx.doi.org/10.1128/CVI.00555-10.
40. Weldon WC, Zarnitsyn VG, Esser ES, Taherbhai MT, Koutsonanos DG, Vassilieva EV, Skountzou I, Prausnitz MR, Compans RW. 2012. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One 7:e41501. http://dx.doi.org/10.1371/journal.pone.0041501.
41. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200. http://dx.doi.org/10.1038/ni758. (Pubitemid 34141451)
42. Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ. 2011. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 377:751-759. http://dx.doi.org/10.1016/S0140-6736(10)62228-3.
43. Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nostbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H. 2011. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 29:8049-8059. http://dx.doi.org/10.1016/j.vaccine.2011.08.042.
44. Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL, Rininger JA, Bowen RA, Reed SG. 2012. Adjuvant solution for pandemic influenza vaccine production. Proc. Natl. Acad. Sci. U. S. A. 109:17585-17590. http://dx.doi.org/10.1073/pnas.1207308109.
45. Schön MP, Schön M. 2007. Imiquimod: mode of action. Br. J. Dermatol. 157(Suppl 2):8-13. http://dx.doi.org/10.1111/j.1365-2133.2007.08265.x. (Pubitemid 350179622)
46. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. 2000. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell. Immunol. 203:55-65. http://dx.doi.org/10.1006/cimm.2000.1673. (Pubitemid 30627030)
47. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. 2006. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314:1936-1938. http://dx.doi.org/10.1126/science.1135299. (Pubitemid 46026117)
48. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, Liu R, Ho KY, Chu KH, Watt CL, Luk WK, Lai KY, Chow FL, Mok T, Buckley T, Chan JF, Wong SS, Zheng B, Chen H, Lau CC, Tse H, Cheng VC, Chan KH, Yuen KY. 2010. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 50:850-859. http://dx.doi.org/10. 1086/650581.
49. Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N. 2012. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to <9 years of age. Pediatr. Infect. Dis. J. 31:e59-65. http://dx.doi.org/10.1097/INF.0b013e31824b9545.
50. Song JY, Cheong HJ, Seo YB, Kim IS, Noh JY, Heo JY, Choi WS, Lee J, Kim WJ. 2012. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. Clin. Vaccine Immunol. 19:638-641. http://dx.doi.org/10.1128/CVI.00026-12.
51. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D. 2012. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J. Infect. Dis. 205:733-744. http://dx.doi.org/10.1093/ infdis/jir641.